Poseida Therapeutics, Inc. (PSTX) Tops Q1 EPS by 16c

Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q1 EPS of ($0.45), $0.16 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $10.34 million versus the consensus estimate of $1.57 million.

For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• S&P 500 may pull back before midterms, but Citi says buy the dip
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue